Multi-Organ-on-a-Chip Technologies: potential impact on predictive substance testing

SMi has confirmed that TissUse, leading pioneers of the Multi-Organ-Chip technology, will be joining the expert speaker lineup for the inaugural conference on 3D Cell Culture. The event will be launched on the 22nd and 23rd of February 2017 in London.

TissUse’s proprietary multi-organ-chip technology platform closely emulates/simulates human biology to achieve uniquely lifelike environments. Connected organs and close physiological context allowremarkably close resemblance to in vivo conditions. This has benefited the drug development process, with current in vitro and animal modelling tests failing to emulate physiological organ complexity within the human body.

Head of Business Development, Reyk Horland, will be leading a spotlight session on multi-organ-chip technologies and its potential impact on predictive substance testing.

A few key points of the presentation include:
* “Human-on-a-chip” technology allows us to closely study organoid interaction
* Alows more representative drug toxicity and efficacy screening.
o Could this be the end of preclinical trials as we know them?
* Closing the gap between in vivo and in vitro
o The importance of highly physiologically relevant cultures and microenvironments.

Reyk will be speaking on Day 2 of the conference.

As 3D cell culture becomes a preferred method for effective and efficient drug development, 3D Cell Culture 2017 will showcase clinical successes and emerging technologies, as well as showcase how this pivotal technique has revolutionized drug discovery and toxicity screening.

The event will also highlight exciting opportunities and latest innovations, spheroid and organoid techniques, as well as key developments in 3D and 4D bio-printing, microfluidics, CRISPR and the ongoing debate of 2D vs 3D cell culture.

In line with this, GE Healthcare Life Sciences will host an exclusive half-day pre-conference workshop on bio-printing on 21st February 2017.

Reyk joins expert speakers from MHRA, Sanofi Aventis, AstraZeneca, Novartis, Lonza, GSK, TissUse and many more. A detailed two-day agenda is available to download on the event website.

For more details about the conference and registration information, visit

3D Cell Culture
22 & 23 February 2017
Copthorne Tara Hotel, London, UK

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at For delegate queries please contact Matthew Apps at For media queries please contact Honey de Gracia at

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at